JP2019524713A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524713A5 JP2019524713A5 JP2019500471A JP2019500471A JP2019524713A5 JP 2019524713 A5 JP2019524713 A5 JP 2019524713A5 JP 2019500471 A JP2019500471 A JP 2019500471A JP 2019500471 A JP2019500471 A JP 2019500471A JP 2019524713 A5 JP2019524713 A5 JP 2019524713A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- dose
- administered
- adc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000611 antibody drug conjugate Substances 0.000 claims description 118
- 108091008116 antibody drug conjugates Proteins 0.000 claims description 118
- 239000003814 drug Substances 0.000 claims description 87
- 108090001123 antibodies Proteins 0.000 claims description 61
- 102000004965 antibodies Human genes 0.000 claims description 61
- 101700073818 CDR1 Proteins 0.000 claims description 47
- 102100002977 CDR1 Human genes 0.000 claims description 47
- 108060001277 CDR2 Proteins 0.000 claims description 42
- 101700027814 CDR3 Proteins 0.000 claims description 42
- 201000011510 cancer Diseases 0.000 claims description 36
- 229940079593 drugs Drugs 0.000 claims description 31
- 230000037396 body weight Effects 0.000 claims description 22
- 239000000562 conjugate Substances 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims description 12
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 10
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 8
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 201000010881 cervical cancer Diseases 0.000 claims description 8
- 238000009115 maintenance therapy Methods 0.000 claims description 8
- 229920001895 acrylonitrile-acrylic-styrene Polymers 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 101700004551 BRAF Proteins 0.000 claims description 6
- 102100004328 BRAF Human genes 0.000 claims description 6
- 229940121647 EGFR inhibitors Drugs 0.000 claims description 6
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims description 6
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 6
- 206010025650 Malignant melanoma Diseases 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 6
- 230000004075 alteration Effects 0.000 claims description 5
- 108010044540 auristatin Proteins 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 206010017758 Gastric cancer Diseases 0.000 claims description 4
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 101700064507 MARK2 Proteins 0.000 claims description 4
- 102100000541 MARK2 Human genes 0.000 claims description 4
- DASWEROEPLKSEI-UIJRFTGLSA-N Monomethyl auristatin E Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 DASWEROEPLKSEI-UIJRFTGLSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 229960001592 Paclitaxel Drugs 0.000 claims description 4
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 201000011231 colorectal cancer Diseases 0.000 claims description 4
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 108010093470 monomethyl auristatin E Proteins 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 4
- 150000003057 platinum Chemical class 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000004434 sulfur atoms Chemical group 0.000 claims description 4
- 229930003347 taxol Natural products 0.000 claims description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 4
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 2
- 229960001686 Afatinib Drugs 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims description 2
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims description 2
- BFSMGDJOXZAERB-UHFFFAOYSA-N Dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 229960001433 Erlotinib Drugs 0.000 claims description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 2
- 101700018422 GAS6 Proteins 0.000 claims description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 2
- 108009000344 Head and Neck Squamous Cell Carcinoma Proteins 0.000 claims description 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 2
- 206010024324 Leukaemias Diseases 0.000 claims description 2
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010028549 Myeloid leukaemia Diseases 0.000 claims description 2
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N Trametinib Chemical group CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 2
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 2
- 201000000053 blastoma Diseases 0.000 claims description 2
- 201000007455 central nervous system cancer Diseases 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 2
- 201000010918 connective tissue cancer Diseases 0.000 claims description 2
- 229960002465 dabrafenib Drugs 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 201000008184 embryoma Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims description 2
- 229960002584 gefitinib Drugs 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 230000002489 hematologic Effects 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 2
- 201000009251 multiple myeloma Diseases 0.000 claims description 2
- 201000002077 muscle cancer Diseases 0.000 claims description 2
- 230000001537 neural Effects 0.000 claims description 2
- 201000004228 ovarian endometrial cancer Diseases 0.000 claims description 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000000498 stomach carcinoma Diseases 0.000 claims description 2
- 210000001519 tissues Anatomy 0.000 claims description 2
- 229960004066 trametinib Drugs 0.000 claims description 2
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 229960003862 vemurafenib Drugs 0.000 claims description 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 2
- 230000003442 weekly Effects 0.000 description 4
- 208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 description 1
- 229940045698 antineoplastic Taxanes Drugs 0.000 description 1
Description
æ¬çºæã¯ããã«ãããã®æ²»çæ¹æ³ã«ããã䜿çšã®ããã®ãåŒïŒ
åŒäžãmAbã¯æAXLæäœã§ãããSã¯è©²æäœã®ç¡«é»ååã§ãããpã¯3ã5ã§ããã®ADCãŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãšãè¬åŠçã«èš±å®¹ãããæ äœãšãå«æããè¬åŠççµæç©ã«é¢ãã該è¬åŠççµæç©ã¯ããããå¿ èŠãšãã察象è ã«ãé£ç¶3é±éã«ãããé±1åã®æäžãšããã®åŸ1é±éã®äŒè¬æéã®ãµã€ã¯ã«ã§ãæäžãããã
[æ¬çºæ1001]
ãããæ²»çããæ¹æ³ã«ããã䜿çšã®ããã®ãããAXLã«çµåããæäœãå«ãæäœè¬ç©ã³ã³ãžã¥ã²ãŒã(ADC)ã§ãã£ãŠã該æ¹æ³ãããããå¿ èŠãšãã察象è ã«å°ãªããšã1ãµã€ã¯ã«ã§è©²ADCãæäžããããšãå«ã¿ã該ãµã€ã¯ã«ããé£ç¶3é±éã«ãããé±1åã®æäžãšããã®åŸã®ADCãæäžããªã1é±éã®äŒè¬æéãšãå«ã¿ãåãµã€ã¯ã«ã®æéã該äŒè¬æéãå«ããŠ28æ¥éã§ããã
該æäœããã¢ãŠãªã¹ã¿ãã³ãŸãã¯ãã®æ©èœæ§ããããé¡äŒŒäœãããã¯èªå°äœã«ãªã³ã«ãŒãä»ããŠã³ã³ãžã¥ã²ãŒããããŠããããã€
(a) ããããSEQ ID No: 36ã37ããã³38ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 39ãGASããã³40ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [107]ïŒ
(b) ããããSEQ ID No: 46ã47ããã³48ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 49ãAASããã³50ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [148]ïŒ
(c) ããããSEQ ID No: 114ã115ããã³116ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 117ãDASããã³118ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [733]ïŒãªãã³ã«
(d) (a)ã(c)ã«ãããŠå®çŸ©ãããåèšæäœã®ãã¡ã®ããããã®ããªã¢ã³ãã§ãã£ãŠã6ã€ã®CDRé åå šäœã«ããã£ãŠã奜ãŸããã¯æ倧ã§1ã2ããŸãã¯3åã®ã¢ããé žæ¹å€ããã奜ãŸããã¯ã¢ããé žçœ®æãäŸãã°ä¿åçã¢ããé žçœ®æãæãããããªã¢ã³ã
ãããªã矀ããéžæãããééå¯å€(VH)é åããã³è»œéå¯å€(VL)é åãå«ããåèšäœ¿çšã®ããã®ADCã
[æ¬çºæ1002]
åèšã¢ãŠãªã¹ã¿ãã³ããã¢ãã¡ãã«ã¢ãŠãªã¹ã¿ãã³E (MMAE)ïŒ
ã§ãããåŒäžãæ³¢ç·ã¯åèšãªã³ã«ãŒãžã®çµåéšäœã瀺ããæ¬çºæ1001ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1003]
åèšãªã³ã«ãŒ-ã¢ãŠãªã¹ã¿ãã³ããvcMMAEïŒ
ã§ãããåŒäžãpã¯1ã8ã®æ°ãäŸãã°3ã5ã奜ãŸããã¯4ãè¡šããSã¯åèšæAXLæäœã®ã¹ã«ããããªã«æ®åºãè¡šããAbã¯è©²æAXLæäœãè¡šããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1004]
ãããæ²»çããæ¹æ³ã«ããã䜿çšã®ããã®ãåŒïŒ
ã®ADCãŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ã§ãã£ãŠãåŒäžã
該æäœã¯ãããAXLã«çµåããããããAXLãžã®çµåã«ã€ããŠGrowth arrest-specific factor 6 (Gas6)ãšç«¶åããã
Sã¯ã該æäœã®ç¡«é»ååã§ããã
pã¯ã3ã5ã®æ°ã§ããã
該æ¹æ³ã§ã¯ããããå¿ èŠãšãã察象è ã«å°ãªããšã1ãµã€ã¯ã«ã§è©²ADCãæäžããã該ãµã€ã¯ã«ããé£ç¶3é±éã«ãããé±1åã®æäžãšããã®åŸã®ADCãæäžããªã1é±éã®äŒè¬æéãšãå«ã¿ãåãµã€ã¯ã«ã®æéã該äŒè¬æéãå«ããŠ28æ¥éã§ããã
åèšäœ¿çšã®ããã®ADCã
[æ¬çºæ1005]
åèšæäœãã
(a) ããããSEQ ID No: 36ã37ããã³38ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 39ãGASããã³40ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [107]ïŒ
(b) ããããSEQ ID No: 46ã47ããã³48ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 49ãAASããã³50ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [148]ïŒ
(c) ããããSEQ ID No: 114ã115ããã³116ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 117ãDASããã³118ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [733]ïŒãªãã³ã«
(d) (a)ã(c)ã«ãããŠå®çŸ©ãããåèšæäœã®ãã¡ã®ããããã®ããªã¢ã³ãã§ãã£ãŠã6ã€ã®CDRé åå šäœã«ããã£ãŠã奜ãŸããã¯æ倧ã§1ã2ããŸãã¯3åã®ã¢ããé žæ¹å€ããã奜ãŸããã¯ã¢ããé žçœ®æãäŸãã°ä¿åçã¢ããé žçœ®æãæãããããªã¢ã³ã
ãããªã矀ããéžæãããVHé åããã³VLé åãå«ããæ¬çºæ1004ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1006]
åèšæäœãã
(a) SEQ ID No: 1ãå«ãVHé åããã³SEQ ID No: 2ãå«ãVLé å [107]ïŒ
(b) SEQ ID No: 5ãå«ãVHé åããã³SEQ ID No: 6ãå«ãVLé å [148]ïŒ
(c) SEQ ID No: 34ãå«ãVHé åããã³SEQ ID No: 35ãå«ãVLé å [733]ïŒ
ãããªã矀ããéžæãããVHé åããã³VLé åãå«ããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1007]
åèšæäœããããããSEQ ID No: 36ã37ããã³38ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 39ãGASããã³40ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [107]ãå«ããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1008]
åèšæäœããSEQ ID No: 1ãå«ãVHé åããã³SEQ ID No: 2ãå«ãVLé å [107]ãå«ããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1009]
åèšæäœããããããSEQ ID No: 46ã47ããã³48ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 49ãAASããã³50ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [148]ãå«ããæ¬çºæ1001ã1006ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1010]
åèšæäœããSEQ ID No: 5ãå«ãVHé åããã³SEQ ID No: 6ãå«ãVLé å [148]ãå«ããæ¬çºæ1009ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1011]
åèšæäœããããããSEQ ID No: 114ã115ããã³116ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 117ãDASããã³118ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [733]ãå«ããæ¬çºæ1001ã1006ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1012]
åèšæäœããSEQ ID No: 34ãå«ãVHé åããã³SEQ ID No: 35ãå«ãVLé å [733]ãå«ããæ¬çºæ1009ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1013]
åèšãªã³ã«ãŒããåèšæäœã®(éšå)éå ã«ãã£ãŠåŸããã該æäœã®ã¹ã«ããããªã«æ®åºã«çµåãããŠãããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1014]
å¹³åçãªpã®æ°ã4ã§ãããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1015]
åèšADCãã28æ¥éã®ãµã€ã¯ã«ã®1æ¥ç®ã8æ¥ç®ãããã³15æ¥ç®ã«æäžããããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1016]
åèšADCã®çšéããåèšå¯Ÿè±¡è ã®äœé1kgããã0.45mgã2.0mgã§ãããäŸãã°ã0.45mg/kgã®çšéã0.5mg/kgã®çšéã0.6mg/kgã®çšéã0.7mg/kgã®çšéã0.8mg/kgã®çšéã0.9mg/kgã®çšéã1.0mg/kgã®çšéã1.1mg/kgã®çšéã1.2mg/kgã®çšéã1.3mg/kgã®çšéã1.4mg/kgã®çšéã1.5mg/kgã®çšéã1.6mg/kgã®çšéã1.7mg/kgã®çšéã1.8mg/kgã®çšéã1.9mg/kgã®çšéããŸãã¯2.0mg/kgã®çšéã§ãããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1017]
åèš28æ¥éã®ãµã€ã¯ã«ã®æ°ãã2ã48ãäŸãã°2ã36ãäŸãã°2ã24ãäŸãã°2ã15ãäŸãã°2ã12ãäŸãã°ã2ãµã€ã¯ã«ã3ãµã€ã¯ã«ã4ãµã€ã¯ã«ã5ãµã€ã¯ã«ã6ãµã€ã¯ã«ã7ãµã€ã¯ã«ã8ãµã€ã¯ã«ã9ãµã€ã¯ã«ã10ãµã€ã¯ã«ã11ãµã€ã¯ã«ããŸãã¯12ãµã€ã¯ã«ã§ãããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1018]
åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã0.45mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1019]
åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã0.6mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ããæ¬çºæ1001ã1017ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1020]
åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã0.8mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ããæ¬çºæ1001ã1017ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1021]
åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã1.0mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ããæ¬çºæ1001ã1017ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1022]
åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã1.2mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ããæ¬çºæ1001ã1017ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1023]
åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã1.4mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ããæ¬çºæ1001ã1017ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1024]
åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã1.6mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ããæ¬çºæ1001ã1017ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1025]
åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã1.8mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ããæ¬çºæ1001ã1017ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1026]
åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã2.0mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ããæ¬çºæ1001ã1017ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1027]
åèšæ²»çãµã€ã¯ã«ã®åŸã«ç¶æçæ³ãå®æœããããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1028]
åèšç¶æçæ³ããåèšADCã3é±éã«1åãäŸãã°21æ¥éãµã€ã¯ã«ã®1æ¥ç®ã«ãæäžããããšãå«ããæ¬çºæ1027ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1029]
åèšç¶æçæ³ã®ããã®ADCã®çšéããåèšå¯Ÿè±¡è ã®äœé1kgããã0.6mgã3.2mgã§ãããäŸãã°ãçŽ0.6mg/kgã®çšéãçŽ0.8mg/kgã®çšéãçŽ1.0mg/kgã®çšéãçŽ1.2mg/kgã®çšéãçŽ1.4mg/kgã®çšéãçŽ1.6mg/kgã®çšéãçŽ1.8mg/kgã®çšéãçŽ2.0mg/kgã®çšéãçŽ2.2mg/kgã®çšéãçŽ2.4mg/kgã®çšéãçŽ2.6mg/kgã®çšéãçŽ2.8mg/kgã®çšéãçŽ3.0mg/kgã®çšéããŸãã¯çŽ3.2mg/kgã®çšéã§ãããæ¬çºæ1027ããã³1028ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1030]
åèšç¶æçæ³ã21æ¥éã®ãµã€ã¯ã«ã§å®æœããã該ãµã€ã¯ã«ã®æ°ãã2ã48ãäŸãã°2ã36ãäŸãã°2ã24ãäŸãã°2ã15ãäŸãã°2ã12ãäŸãã°ã2ãµã€ã¯ã«ã3ãµã€ã¯ã«ã4ãµã€ã¯ã«ã5ãµã€ã¯ã«ã6ãµã€ã¯ã«ã7ãµã€ã¯ã«ã8ãµã€ã¯ã«ã9ãµã€ã¯ã«ã10ãµã€ã¯ã«ã11ãµã€ã¯ã«ããŸãã¯12ãµã€ã¯ã«ã§ãããæ¬çºæ1027ã1029ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1031]
åèšããããAXLãçºçŸããåºåœ¢è «çãå«ããããŸãã¯AXLãçºçŸããè¡æ¶²ããã§ãããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1032]
åèšAXLãçºçŸããè¡æ¶²ããããçœè¡ç ãäŸãã°ãæ ¢æ§ãªã³ãæ§çœè¡ç ã骚é«æ§çœè¡ç ãæ¥æ§éªšé«æ§çœè¡ç (AML)ãããã³æ ¢æ§éªšé«æ§çœè¡ç ïŒãªã³ãè «ãäŸãã°éããžãã³ãªã³ãè «ããã³å€çºæ§éªšé«è «ãããªã矀ããéžæããããæ¬çºæ1031ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1033]
åèšããããAXLãçºçŸããåºåœ¢è «çãå«ã¿ããã€èºçãäŸãã°ãéå°çŽ°èèºç(NSCLC)ããã³èºæå¹³äžç®çïŒå©Šäººç§çãäŸãã°ãåµå·£çãåå®®å èçãŸãã¯åå®®é žçïŒç²ç¶è ºçïŒç®èçãäŸãã°ãé»è²è «ïŒå€§è žçãäŸãã°ãå€§è žçè «ããã³å€§è žè ºçïŒèè±çïŒéªšãããäŸãã°è»éªšèè «ïŒä¹³çãäŸãã°ããªãã«ãã¬ãã£ãä¹³çïŒäžæ¢ç¥çµç³»ã®çãäŸãã°ãè èœè «ãæç¶çŽ°èè «ããã³ç¥çµèœçŽ°èè «ïŒçµåçµç¹çïŒç·ç¶èœçŽ°èçïŒèçãäŸãã°èçè «ïŒé é žéšçïŒè èçïŒèèçãäŸãã°è现èçïŒçèçïŒç¥çµçµç¹çïŒèµèçãäŸãã°ãèµç®¡çããã³èµè ºçïŒãªãã³ã«è»éšçµç¹èè «ãããªã矀ããéžæããããæ¬çºæ1031ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1034]
åèšããããéå°çŽ°èèºç(NSCLC)ãåµå·£çãåå®®å èçãåå®®é žçãç²ç¶è ºçãããªã矀ããéžæããããæ¬çºæ1033ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1035]
åèšããããããã·ã³ãããŒãŒé»å®³å€ãã»ãªã³/ãã¬ãªãã³ãããŒãŒé»å®³å€ããã³ååŠçæ³å€ãããªã矀ããéžæãããå°ãªããšã1ã€ã®æ²»çå€ã«å¯ŸããŠèæ§ã§ãããæ¬çºæ1031ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1036]
åèšããã·ã³ãããŒãŒé»å®³å€ãEGFRé»å®³å€ã§ãããåèšã»ãªã³/ãã¬ãªãã³ãããŒãŒé»å®³å€ãBRAFé»å®³å€ããã³MEKé»å®³å€ãããªã矀ããéžæããããæ¬çºæ1035ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1037]
åèšããããNSCLCãåµå·£çãåå®®é žçãé»è²è «ãé é žéšæå¹³äžç®ç(SCCHN)ãä¹³çãæ¶å管éè³ªè «ç(GIST)ãè èçãåç«è ºçãç¥çµèœçŽ°èè «ãèµèçãé£éçã暪çŽçèè «ãæ¥æ§éªšé«æ§çœè¡ç (AML)ããŸãã¯æ ¢æ§éªšé«æ§çœè¡ç (CML)ããéžæããããæ¬çºæ1035ããã³1036ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1038]
åèšããããEGFRé»å®³å€ã«èæ§ã®ããNSCLCã§ãããæ¬çºæ1037ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1039]
åèšEGFRé»å®³å€ãããšã«ãããããã²ãã£ãããããã³ã¢ãã¡ãããã®ãã¡ã®å°ãªããšã1ã€ã§ãããæ¬çºæ1038ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1040]
åèšããããã¿ããµã³ãŸãã¯çœéèªå°äœã«èæ§ã®ããåµå·£çã§ãããæ¬çºæ1037ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1041]
åèšã¿ããµã³ããã¯ãªã¿ãã»ã«ã§ãããåèšçœéèªå°äœãã·ã¹ãã©ãã³ã§ãããæ¬çºæ1040ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1042]
åèšããããã¿ããµã³ã«èæ§ã®ããåå®®é žçã§ãããæ¬çºæ1037ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1043]
åèšã¿ããµã³ãããã¯ãªã¿ãã»ã«ããã³ãã»ã¿ãã»ã«ã®ãã¡ã®å°ãªããšãäžæ¹ã§ãããæ¬çºæ1042ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1044]
åèšããããBRAFé»å®³å€ããã³/ãŸãã¯MEKé»å®³å€ã«èæ§ã®ããé»è²è «ã§ãããæ¬çºæ1037ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1045]
åèšBRAFé»å®³å€ããã ã©ãã§ããããã³ããã©ãã§ããã®ãã¡ã®å°ãªããšãäžæ¹ã§ãããåèšMEKé»å®³å€ããã©ã¡ãããã§ãããæ¬çºæ1044ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1046]
åèšADCããå°ãªããšã1ã€ã®ä»ã®æããå€ãšã®çµã¿åããã§äœ¿çšããããã®ãã®ã§ãããæ¬çºæ1035ã1045ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1047]
åèšå°ãªããšã1ã€ã®ä»ã®æããå€ããæ¬çºæ1035ã1045ã®ããããã®å°ãªããšã1ã€ã®æ²»çå€ãå«ã¿ãåèšããããåèšçµã¿åããã«ãããå°ãªããšã1ã€ã®æ²»çå€ã«å¯ŸããŠèæ§ã§ãããæ¬çºæ1046ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1048]
åèšADCãè¬åŠççµæç©äžã«å«ãŸãããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1049]
åèšè¬åŠççµæç©ãè¬åŠçã«èš±å®¹ãããæ äœãããã«å«ããæ¬çºæ1048ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1050]
åèšè¬åŠççµæç©ãã泚å°ãŸãã¯æ³šå ¥ã«ããã奜ãŸããã¯éèå æ³šå ¥ãšããŠãæäžããããæ¬çºæ1048ããã³1049ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1051]
察象è ã«ããããããæ²»çããããã®æ¹æ³ã§ãã£ãŠããããå¿ èŠãšãã察象è ã«å°ãªããšã1ãµã€ã¯ã«ã®æ²»çãµã€ã¯ã«ã§ADCãæäžããããšãå«ã¿ã該治çãµã€ã¯ã«ããé£ç¶3é±éã«ãããé±1åã®è©²ADCã®æäžãšããã®åŸã®è©²ADCãæäžããªã1é±éã®äŒè¬æéãšãå«ã¿ãåãµã€ã¯ã«ã®æéã該äŒè¬æéãå«ããŠ28æ¥éã§ããã該ADCããããAXLã«çµåããæäœãå«ã¿ããã€ã¢ãŠãªã¹ã¿ãã³ãŸãã¯ãã®æ©èœæ§ããããé¡äŒŒäœãããã¯èªå°äœã«ãªã³ã«ãŒãä»ããŠã³ã³ãžã¥ã²ãŒããããŠãããåèšæ¹æ³ã
[æ¬çºæ1052]
察象è ã«ããããããæ²»çããããã®æ¹æ³ã§ãã£ãŠããããå¿ èŠãšãã察象è ã«å°ãªããšã1ãµã€ã¯ã«ã®æ²»çãµã€ã¯ã«ã§æäžããããšãå«ã¿ã該治çãµã€ã¯ã«ããé£ç¶3é±éã«ãããé±1åã®ADCã®æäžãšããã®åŸã®è©²ADCãæäžããªã1é±éã®äŒè¬æéãšãå«ã¿ãåãµã€ã¯ã«æéã該äŒè¬æéãå«ããŠ28æ¥éã§ããã該ADCãåŒïŒ
ã§è¡šãããããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ã§ãããåŒäžã
Abã¯ãããAXLã«çµåããæäœã§ããã
Sã¯ã該æäœã®ç¡«é»ååã§ããã
pã¯ã3ã5ã®æ°ã奜ãŸããã¯4ã§ããã
åèšæ¹æ³ã
[æ¬çºæ1053]
åèšæäœãã
(a) ããããSEQ ID No: 36ã37ããã³38ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 39ãGASããã³40ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [107]ïŒ
(b) ããããSEQ ID No: 46ã47ããã³48ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 49ãAASããã³50ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [148]ïŒ
(c) ããããSEQ ID No: 114ã115ããã³116ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 117ãDASããã³118ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [733]ïŒãªãã³ã«
(d) (a)ã(c)ã«ãããŠå®çŸ©ãããåèšæäœã®ãã¡ã®ããããã®ããªã¢ã³ãã§ãã£ãŠã6ã€ã®CDRé åå šäœã«ããã£ãŠã奜ãŸããã¯æ倧ã§1ã2ããŸãã¯3åã®ã¢ããé žæ¹å€ããã奜ãŸããã¯ã¢ããé žçœ®æãäŸãã°ä¿åçã¢ããé žçœ®æãæãããããªã¢ã³ã
ãããªã矀ããéžæãããVHé åããã³VLé åãå«ããæ¬çºæ1051ããã³1052ã®ããããã®æ¹æ³ã
[æ¬çºæ1054]
æ¬çºæ1001ã1050ã®ããããã®äœ¿çšã®ããã®ADCã®ç¹åŸŽãå«ããæ¬çºæ1051ã1053ã®ããããã®æ¹æ³ã
åŒäžãmAbã¯æAXLæäœã§ãããSã¯è©²æäœã®ç¡«é»ååã§ãããpã¯3ã5ã§ããã®ADCãŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãšãè¬åŠçã«èš±å®¹ãããæ äœãšãå«æããè¬åŠççµæç©ã«é¢ãã該è¬åŠççµæç©ã¯ããããå¿ èŠãšãã察象è ã«ãé£ç¶3é±éã«ãããé±1åã®æäžãšããã®åŸ1é±éã®äŒè¬æéã®ãµã€ã¯ã«ã§ãæäžãããã
[æ¬çºæ1001]
ãããæ²»çããæ¹æ³ã«ããã䜿çšã®ããã®ãããAXLã«çµåããæäœãå«ãæäœè¬ç©ã³ã³ãžã¥ã²ãŒã(ADC)ã§ãã£ãŠã該æ¹æ³ãããããå¿ èŠãšãã察象è ã«å°ãªããšã1ãµã€ã¯ã«ã§è©²ADCãæäžããããšãå«ã¿ã該ãµã€ã¯ã«ããé£ç¶3é±éã«ãããé±1åã®æäžãšããã®åŸã®ADCãæäžããªã1é±éã®äŒè¬æéãšãå«ã¿ãåãµã€ã¯ã«ã®æéã該äŒè¬æéãå«ããŠ28æ¥éã§ããã
該æäœããã¢ãŠãªã¹ã¿ãã³ãŸãã¯ãã®æ©èœæ§ããããé¡äŒŒäœãããã¯èªå°äœã«ãªã³ã«ãŒãä»ããŠã³ã³ãžã¥ã²ãŒããããŠããããã€
(a) ããããSEQ ID No: 36ã37ããã³38ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 39ãGASããã³40ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [107]ïŒ
(b) ããããSEQ ID No: 46ã47ããã³48ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 49ãAASããã³50ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [148]ïŒ
(c) ããããSEQ ID No: 114ã115ããã³116ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 117ãDASããã³118ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [733]ïŒãªãã³ã«
(d) (a)ã(c)ã«ãããŠå®çŸ©ãããåèšæäœã®ãã¡ã®ããããã®ããªã¢ã³ãã§ãã£ãŠã6ã€ã®CDRé åå šäœã«ããã£ãŠã奜ãŸããã¯æ倧ã§1ã2ããŸãã¯3åã®ã¢ããé žæ¹å€ããã奜ãŸããã¯ã¢ããé žçœ®æãäŸãã°ä¿åçã¢ããé žçœ®æãæãããããªã¢ã³ã
ãããªã矀ããéžæãããééå¯å€(VH)é åããã³è»œéå¯å€(VL)é åãå«ããåèšäœ¿çšã®ããã®ADCã
[æ¬çºæ1002]
åèšã¢ãŠãªã¹ã¿ãã³ããã¢ãã¡ãã«ã¢ãŠãªã¹ã¿ãã³E (MMAE)ïŒ
ã§ãããåŒäžãæ³¢ç·ã¯åèšãªã³ã«ãŒãžã®çµåéšäœã瀺ããæ¬çºæ1001ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1003]
åèšãªã³ã«ãŒ-ã¢ãŠãªã¹ã¿ãã³ããvcMMAEïŒ
ã§ãããåŒäžãpã¯1ã8ã®æ°ãäŸãã°3ã5ã奜ãŸããã¯4ãè¡šããSã¯åèšæAXLæäœã®ã¹ã«ããããªã«æ®åºãè¡šããAbã¯è©²æAXLæäœãè¡šããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1004]
ãããæ²»çããæ¹æ³ã«ããã䜿çšã®ããã®ãåŒïŒ
ã®ADCãŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ã§ãã£ãŠãåŒäžã
該æäœã¯ãããAXLã«çµåããããããAXLãžã®çµåã«ã€ããŠGrowth arrest-specific factor 6 (Gas6)ãšç«¶åããã
Sã¯ã該æäœã®ç¡«é»ååã§ããã
pã¯ã3ã5ã®æ°ã§ããã
該æ¹æ³ã§ã¯ããããå¿ èŠãšãã察象è ã«å°ãªããšã1ãµã€ã¯ã«ã§è©²ADCãæäžããã該ãµã€ã¯ã«ããé£ç¶3é±éã«ãããé±1åã®æäžãšããã®åŸã®ADCãæäžããªã1é±éã®äŒè¬æéãšãå«ã¿ãåãµã€ã¯ã«ã®æéã該äŒè¬æéãå«ããŠ28æ¥éã§ããã
åèšäœ¿çšã®ããã®ADCã
[æ¬çºæ1005]
åèšæäœãã
(a) ããããSEQ ID No: 36ã37ããã³38ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 39ãGASããã³40ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [107]ïŒ
(b) ããããSEQ ID No: 46ã47ããã³48ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 49ãAASããã³50ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [148]ïŒ
(c) ããããSEQ ID No: 114ã115ããã³116ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 117ãDASããã³118ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [733]ïŒãªãã³ã«
(d) (a)ã(c)ã«ãããŠå®çŸ©ãããåèšæäœã®ãã¡ã®ããããã®ããªã¢ã³ãã§ãã£ãŠã6ã€ã®CDRé åå šäœã«ããã£ãŠã奜ãŸããã¯æ倧ã§1ã2ããŸãã¯3åã®ã¢ããé žæ¹å€ããã奜ãŸããã¯ã¢ããé žçœ®æãäŸãã°ä¿åçã¢ããé žçœ®æãæãããããªã¢ã³ã
ãããªã矀ããéžæãããVHé åããã³VLé åãå«ããæ¬çºæ1004ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1006]
åèšæäœãã
(a) SEQ ID No: 1ãå«ãVHé åããã³SEQ ID No: 2ãå«ãVLé å [107]ïŒ
(b) SEQ ID No: 5ãå«ãVHé åããã³SEQ ID No: 6ãå«ãVLé å [148]ïŒ
(c) SEQ ID No: 34ãå«ãVHé åããã³SEQ ID No: 35ãå«ãVLé å [733]ïŒ
ãããªã矀ããéžæãããVHé åããã³VLé åãå«ããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1007]
åèšæäœããããããSEQ ID No: 36ã37ããã³38ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 39ãGASããã³40ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [107]ãå«ããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1008]
åèšæäœããSEQ ID No: 1ãå«ãVHé åããã³SEQ ID No: 2ãå«ãVLé å [107]ãå«ããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1009]
åèšæäœããããããSEQ ID No: 46ã47ããã³48ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 49ãAASããã³50ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [148]ãå«ããæ¬çºæ1001ã1006ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1010]
åèšæäœããSEQ ID No: 5ãå«ãVHé åããã³SEQ ID No: 6ãå«ãVLé å [148]ãå«ããæ¬çºæ1009ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1011]
åèšæäœããããããSEQ ID No: 114ã115ããã³116ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 117ãDASããã³118ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [733]ãå«ããæ¬çºæ1001ã1006ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1012]
åèšæäœããSEQ ID No: 34ãå«ãVHé åããã³SEQ ID No: 35ãå«ãVLé å [733]ãå«ããæ¬çºæ1009ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1013]
åèšãªã³ã«ãŒããåèšæäœã®(éšå)éå ã«ãã£ãŠåŸããã該æäœã®ã¹ã«ããããªã«æ®åºã«çµåãããŠãããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1014]
å¹³åçãªpã®æ°ã4ã§ãããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1015]
åèšADCãã28æ¥éã®ãµã€ã¯ã«ã®1æ¥ç®ã8æ¥ç®ãããã³15æ¥ç®ã«æäžããããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1016]
åèšADCã®çšéããåèšå¯Ÿè±¡è ã®äœé1kgããã0.45mgã2.0mgã§ãããäŸãã°ã0.45mg/kgã®çšéã0.5mg/kgã®çšéã0.6mg/kgã®çšéã0.7mg/kgã®çšéã0.8mg/kgã®çšéã0.9mg/kgã®çšéã1.0mg/kgã®çšéã1.1mg/kgã®çšéã1.2mg/kgã®çšéã1.3mg/kgã®çšéã1.4mg/kgã®çšéã1.5mg/kgã®çšéã1.6mg/kgã®çšéã1.7mg/kgã®çšéã1.8mg/kgã®çšéã1.9mg/kgã®çšéããŸãã¯2.0mg/kgã®çšéã§ãããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1017]
åèš28æ¥éã®ãµã€ã¯ã«ã®æ°ãã2ã48ãäŸãã°2ã36ãäŸãã°2ã24ãäŸãã°2ã15ãäŸãã°2ã12ãäŸãã°ã2ãµã€ã¯ã«ã3ãµã€ã¯ã«ã4ãµã€ã¯ã«ã5ãµã€ã¯ã«ã6ãµã€ã¯ã«ã7ãµã€ã¯ã«ã8ãµã€ã¯ã«ã9ãµã€ã¯ã«ã10ãµã€ã¯ã«ã11ãµã€ã¯ã«ããŸãã¯12ãµã€ã¯ã«ã§ãããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1018]
åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã0.45mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1019]
åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã0.6mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ããæ¬çºæ1001ã1017ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1020]
åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã0.8mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ããæ¬çºæ1001ã1017ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1021]
åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã1.0mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ããæ¬çºæ1001ã1017ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1022]
åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã1.2mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ããæ¬çºæ1001ã1017ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1023]
åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã1.4mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ããæ¬çºæ1001ã1017ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1024]
åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã1.6mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ããæ¬çºæ1001ã1017ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1025]
åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã1.8mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ããæ¬çºæ1001ã1017ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1026]
åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã2.0mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ããæ¬çºæ1001ã1017ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1027]
åèšæ²»çãµã€ã¯ã«ã®åŸã«ç¶æçæ³ãå®æœããããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1028]
åèšç¶æçæ³ããåèšADCã3é±éã«1åãäŸãã°21æ¥éãµã€ã¯ã«ã®1æ¥ç®ã«ãæäžããããšãå«ããæ¬çºæ1027ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1029]
åèšç¶æçæ³ã®ããã®ADCã®çšéããåèšå¯Ÿè±¡è ã®äœé1kgããã0.6mgã3.2mgã§ãããäŸãã°ãçŽ0.6mg/kgã®çšéãçŽ0.8mg/kgã®çšéãçŽ1.0mg/kgã®çšéãçŽ1.2mg/kgã®çšéãçŽ1.4mg/kgã®çšéãçŽ1.6mg/kgã®çšéãçŽ1.8mg/kgã®çšéãçŽ2.0mg/kgã®çšéãçŽ2.2mg/kgã®çšéãçŽ2.4mg/kgã®çšéãçŽ2.6mg/kgã®çšéãçŽ2.8mg/kgã®çšéãçŽ3.0mg/kgã®çšéããŸãã¯çŽ3.2mg/kgã®çšéã§ãããæ¬çºæ1027ããã³1028ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1030]
åèšç¶æçæ³ã21æ¥éã®ãµã€ã¯ã«ã§å®æœããã該ãµã€ã¯ã«ã®æ°ãã2ã48ãäŸãã°2ã36ãäŸãã°2ã24ãäŸãã°2ã15ãäŸãã°2ã12ãäŸãã°ã2ãµã€ã¯ã«ã3ãµã€ã¯ã«ã4ãµã€ã¯ã«ã5ãµã€ã¯ã«ã6ãµã€ã¯ã«ã7ãµã€ã¯ã«ã8ãµã€ã¯ã«ã9ãµã€ã¯ã«ã10ãµã€ã¯ã«ã11ãµã€ã¯ã«ããŸãã¯12ãµã€ã¯ã«ã§ãããæ¬çºæ1027ã1029ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1031]
åèšããããAXLãçºçŸããåºåœ¢è «çãå«ããããŸãã¯AXLãçºçŸããè¡æ¶²ããã§ãããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1032]
åèšAXLãçºçŸããè¡æ¶²ããããçœè¡ç ãäŸãã°ãæ ¢æ§ãªã³ãæ§çœè¡ç ã骚é«æ§çœè¡ç ãæ¥æ§éªšé«æ§çœè¡ç (AML)ãããã³æ ¢æ§éªšé«æ§çœè¡ç ïŒãªã³ãè «ãäŸãã°éããžãã³ãªã³ãè «ããã³å€çºæ§éªšé«è «ãããªã矀ããéžæããããæ¬çºæ1031ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1033]
åèšããããAXLãçºçŸããåºåœ¢è «çãå«ã¿ããã€èºçãäŸãã°ãéå°çŽ°èèºç(NSCLC)ããã³èºæå¹³äžç®çïŒå©Šäººç§çãäŸãã°ãåµå·£çãåå®®å èçãŸãã¯åå®®é žçïŒç²ç¶è ºçïŒç®èçãäŸãã°ãé»è²è «ïŒå€§è žçãäŸãã°ãå€§è žçè «ããã³å€§è žè ºçïŒèè±çïŒéªšãããäŸãã°è»éªšèè «ïŒä¹³çãäŸãã°ããªãã«ãã¬ãã£ãä¹³çïŒäžæ¢ç¥çµç³»ã®çãäŸãã°ãè èœè «ãæç¶çŽ°èè «ããã³ç¥çµèœçŽ°èè «ïŒçµåçµç¹çïŒç·ç¶èœçŽ°èçïŒèçãäŸãã°èçè «ïŒé é žéšçïŒè èçïŒèèçãäŸãã°è现èçïŒçèçïŒç¥çµçµç¹çïŒèµèçãäŸãã°ãèµç®¡çããã³èµè ºçïŒãªãã³ã«è»éšçµç¹èè «ãããªã矀ããéžæããããæ¬çºæ1031ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1034]
åèšããããéå°çŽ°èèºç(NSCLC)ãåµå·£çãåå®®å èçãåå®®é žçãç²ç¶è ºçãããªã矀ããéžæããããæ¬çºæ1033ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1035]
åèšããããããã·ã³ãããŒãŒé»å®³å€ãã»ãªã³/ãã¬ãªãã³ãããŒãŒé»å®³å€ããã³ååŠçæ³å€ãããªã矀ããéžæãããå°ãªããšã1ã€ã®æ²»çå€ã«å¯ŸããŠèæ§ã§ãããæ¬çºæ1031ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1036]
åèšããã·ã³ãããŒãŒé»å®³å€ãEGFRé»å®³å€ã§ãããåèšã»ãªã³/ãã¬ãªãã³ãããŒãŒé»å®³å€ãBRAFé»å®³å€ããã³MEKé»å®³å€ãããªã矀ããéžæããããæ¬çºæ1035ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1037]
åèšããããNSCLCãåµå·£çãåå®®é žçãé»è²è «ãé é žéšæå¹³äžç®ç(SCCHN)ãä¹³çãæ¶å管éè³ªè «ç(GIST)ãè èçãåç«è ºçãç¥çµèœçŽ°èè «ãèµèçãé£éçã暪çŽçèè «ãæ¥æ§éªšé«æ§çœè¡ç (AML)ããŸãã¯æ ¢æ§éªšé«æ§çœè¡ç (CML)ããéžæããããæ¬çºæ1035ããã³1036ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1038]
åèšããããEGFRé»å®³å€ã«èæ§ã®ããNSCLCã§ãããæ¬çºæ1037ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1039]
åèšEGFRé»å®³å€ãããšã«ãããããã²ãã£ãããããã³ã¢ãã¡ãããã®ãã¡ã®å°ãªããšã1ã€ã§ãããæ¬çºæ1038ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1040]
åèšããããã¿ããµã³ãŸãã¯çœéèªå°äœã«èæ§ã®ããåµå·£çã§ãããæ¬çºæ1037ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1041]
åèšã¿ããµã³ããã¯ãªã¿ãã»ã«ã§ãããåèšçœéèªå°äœãã·ã¹ãã©ãã³ã§ãããæ¬çºæ1040ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1042]
åèšããããã¿ããµã³ã«èæ§ã®ããåå®®é žçã§ãããæ¬çºæ1037ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1043]
åèšã¿ããµã³ãããã¯ãªã¿ãã»ã«ããã³ãã»ã¿ãã»ã«ã®ãã¡ã®å°ãªããšãäžæ¹ã§ãããæ¬çºæ1042ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1044]
åèšããããBRAFé»å®³å€ããã³/ãŸãã¯MEKé»å®³å€ã«èæ§ã®ããé»è²è «ã§ãããæ¬çºæ1037ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1045]
åèšBRAFé»å®³å€ããã ã©ãã§ããããã³ããã©ãã§ããã®ãã¡ã®å°ãªããšãäžæ¹ã§ãããåèšMEKé»å®³å€ããã©ã¡ãããã§ãããæ¬çºæ1044ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1046]
åèšADCããå°ãªããšã1ã€ã®ä»ã®æããå€ãšã®çµã¿åããã§äœ¿çšããããã®ãã®ã§ãããæ¬çºæ1035ã1045ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1047]
åèšå°ãªããšã1ã€ã®ä»ã®æããå€ããæ¬çºæ1035ã1045ã®ããããã®å°ãªããšã1ã€ã®æ²»çå€ãå«ã¿ãåèšããããåèšçµã¿åããã«ãããå°ãªããšã1ã€ã®æ²»çå€ã«å¯ŸããŠèæ§ã§ãããæ¬çºæ1046ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1048]
åèšADCãè¬åŠççµæç©äžã«å«ãŸãããåèšæ¬çºæã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1049]
åèšè¬åŠççµæç©ãè¬åŠçã«èš±å®¹ãããæ äœãããã«å«ããæ¬çºæ1048ã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1050]
åèšè¬åŠççµæç©ãã泚å°ãŸãã¯æ³šå ¥ã«ããã奜ãŸããã¯éèå æ³šå ¥ãšããŠãæäžããããæ¬çºæ1048ããã³1049ã®ããããã®äœ¿çšã®ããã®ADCã
[æ¬çºæ1051]
察象è ã«ããããããæ²»çããããã®æ¹æ³ã§ãã£ãŠããããå¿ èŠãšãã察象è ã«å°ãªããšã1ãµã€ã¯ã«ã®æ²»çãµã€ã¯ã«ã§ADCãæäžããããšãå«ã¿ã該治çãµã€ã¯ã«ããé£ç¶3é±éã«ãããé±1åã®è©²ADCã®æäžãšããã®åŸã®è©²ADCãæäžããªã1é±éã®äŒè¬æéãšãå«ã¿ãåãµã€ã¯ã«ã®æéã該äŒè¬æéãå«ããŠ28æ¥éã§ããã該ADCããããAXLã«çµåããæäœãå«ã¿ããã€ã¢ãŠãªã¹ã¿ãã³ãŸãã¯ãã®æ©èœæ§ããããé¡äŒŒäœãããã¯èªå°äœã«ãªã³ã«ãŒãä»ããŠã³ã³ãžã¥ã²ãŒããããŠãããåèšæ¹æ³ã
[æ¬çºæ1052]
察象è ã«ããããããæ²»çããããã®æ¹æ³ã§ãã£ãŠããããå¿ èŠãšãã察象è ã«å°ãªããšã1ãµã€ã¯ã«ã®æ²»çãµã€ã¯ã«ã§æäžããããšãå«ã¿ã該治çãµã€ã¯ã«ããé£ç¶3é±éã«ãããé±1åã®ADCã®æäžãšããã®åŸã®è©²ADCãæäžããªã1é±éã®äŒè¬æéãšãå«ã¿ãåãµã€ã¯ã«æéã該äŒè¬æéãå«ããŠ28æ¥éã§ããã該ADCãåŒïŒ
ã§è¡šãããããŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ã§ãããåŒäžã
Abã¯ãããAXLã«çµåããæäœã§ããã
Sã¯ã該æäœã®ç¡«é»ååã§ããã
pã¯ã3ã5ã®æ°ã奜ãŸããã¯4ã§ããã
åèšæ¹æ³ã
[æ¬çºæ1053]
åèšæäœãã
(a) ããããSEQ ID No: 36ã37ããã³38ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 39ãGASããã³40ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [107]ïŒ
(b) ããããSEQ ID No: 46ã47ããã³48ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 49ãAASããã³50ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [148]ïŒ
(c) ããããSEQ ID No: 114ã115ããã³116ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 117ãDASããã³118ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [733]ïŒãªãã³ã«
(d) (a)ã(c)ã«ãããŠå®çŸ©ãããåèšæäœã®ãã¡ã®ããããã®ããªã¢ã³ãã§ãã£ãŠã6ã€ã®CDRé åå šäœã«ããã£ãŠã奜ãŸããã¯æ倧ã§1ã2ããŸãã¯3åã®ã¢ããé žæ¹å€ããã奜ãŸããã¯ã¢ããé žçœ®æãäŸãã°ä¿åçã¢ããé žçœ®æãæãããããªã¢ã³ã
ãããªã矀ããéžæãããVHé åããã³VLé åãå«ããæ¬çºæ1051ããã³1052ã®ããããã®æ¹æ³ã
[æ¬çºæ1054]
æ¬çºæ1001ã1050ã®ããããã®äœ¿çšã®ããã®ADCã®ç¹åŸŽãå«ããæ¬çºæ1051ã1053ã®ããããã®æ¹æ³ã
Claims (50)
- ããAXLã«çµåããæäœãå«ãæäœè¬ç©ã³ã³ãžã¥ã²ãŒã(ADC)ãå«ããçãæ²»çããããã®å»è¬ã§ãã£ãŠã
該å»è¬ãããããå¿ èŠãšãã察象è ã«å°ãªããšã1ãµã€ã¯ã«ã§è©²ADCãæäžããããã«çšããããããšãç¹åŸŽãšãã該ãµã€ã¯ã«ããé£ç¶3é±éã«ãããé±1åã®æäžãšããã®åŸã®ADCãæäžããªã1é±éã®äŒè¬æéãšãå«ã¿ãåãµã€ã¯ã«ã®æéã該äŒè¬æéãå«ããŠ28æ¥éã§ããã
該æäœããã¢ãŠãªã¹ã¿ãã³ãŸãã¯ãã®æ©èœæ§ããããé¡äŒŒäœãããã¯èªå°äœã«ãªã³ã«ãŒãä»ããŠã³ã³ãžã¥ã²ãŒããããŠããããã€
(a) ããããSEQ ID No: 36ãSEQ ID No: 37ããã³SEQ ID No: 38ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 39ãGASããã³SEQ ID No: 40ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [107]ïŒ
(b) ããããSEQ ID No: 46ãSEQ ID No: 47ããã³SEQ ID No: 48ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 49ãAASããã³SEQ ID No: 50ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [148]ïŒ
(c) ããããSEQ ID No: 114ãSEQ ID No: 115ããã³SEQ ID No: 116ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 117ãDASããã³SEQ ID No: 118ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [733]ïŒãªãã³ã«
(d) (a)ã(c)ã«ãããŠå®çŸ©ãããåèšæäœã®ãã¡ã®ããããã®ããªã¢ã³ãã§ãã£ãŠã6ã€ã®CDRé åå šäœã«ããã£ãŠã奜ãŸããã¯æ倧ã§1ã2ããŸãã¯3åã®ã¢ããé žæ¹å€ããã奜ãŸããã¯ã¢ããé žçœ®æãäŸãã°ä¿åçã¢ããé žçœ®æãæãããããªã¢ã³ã
ãããªã矀ããéžæãããééå¯å€(VH)é åããã³è»œéå¯å€(VL)é åãå«ãã
å»è¬ã - åŒïŒ
ã®ADCãŸãã¯ãã®è¬åŠçã«èš±å®¹ãããå¡©ãå«ãããããæ²»çããããã®å»è¬ã§ãã£ãŠãåŒäžã
該æäœã¯ãããAXLã«çµåããããããAXLãžã®çµåã«ã€ããŠGrowth arrest-specific factor 6 (Gas6)ãšç«¶åããã
Sã¯ã該æäœã®ç¡«é»ååã§ããã
pã¯ã3ã5ã®æ°ã§ããã
該å»è¬ãããããå¿ èŠãšãã察象è ã«å°ãªããšã1ãµã€ã¯ã«ã§è©²ADCãæäžãããããã«çšããããããšãç¹åŸŽãšãã該ãµã€ã¯ã«ããé£ç¶3é±éã«ãããé±1åã®æäžãšããã®åŸã®ADCãæäžããªã1é±éã®äŒè¬æéãšãå«ã¿ãåãµã€ã¯ã«ã®æéã該äŒè¬æéãå«ããŠ28æ¥éã§ããã
å»è¬ã - åèšæäœãã
(a) ããããSEQ ID No: 36ãSEQ ID No: 37ããã³SEQ ID No: 38ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 39ãGASããã³SEQ ID No: 40ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [107]ïŒ
(b) ããããSEQ ID No: 46ãSEQ ID No: 47ããã³SEQ ID No: 48ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 49ãAASããã³SEQ ID No: 50ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [148]ïŒ
(c) ããããSEQ ID No: 114ãSEQ ID No: 115ããã³SEQ ID No: 116ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 117ãDASããã³SEQ ID No: 118ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [733]ïŒãªãã³ã«
(d) (a)ã(c)ã«ãããŠå®çŸ©ãããåèšæäœã®ãã¡ã®ããããã®ããªã¢ã³ãã§ãã£ãŠã6ã€ã®CDRé åå šäœã«ããã£ãŠã奜ãŸããã¯æ倧ã§1ã2ããŸãã¯3åã®ã¢ããé žæ¹å€ããã奜ãŸããã¯ã¢ããé žçœ®æãäŸãã°ä¿åçã¢ããé žçœ®æãæãããããªã¢ã³ã
ãããªã矀ããéžæãããVHé åããã³VLé åãå«ããè«æ±é 4ã«èšèŒã®å»è¬ã - åèšæäœãã
(a) SEQ ID No: 1ãå«ãVHé åããã³SEQ ID No: 2ãå«ãVLé å [107]ïŒ
(b) SEQ ID No: 5ãå«ãVHé åããã³SEQ ID No: 6ãå«ãVLé å [148]ïŒãªãã³ã«
(c) SEQ ID No: 34ãå«ãVHé åããã³SEQ ID No: 35ãå«ãVLé å [733]ïŒ
ãããªã矀ããéžæãããVHé åããã³VLé åãå«ããè«æ±é 1ã5ã®ããããäžé ã«èšèŒã®å»è¬ã - åèšæäœããããããSEQ ID No: 36ãSEQ ID No: 37ããã³SEQ ID No: 38ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 39ãGASããã³SEQ ID No: 40ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [107]ãå«ããè«æ±é 1ã6ã®ããããäžé ã«èšèŒã®å»è¬ã
- åèšæäœããSEQ ID No: 1ãå«ãVHé åããã³SEQ ID No: 2ãå«ãVLé å [107]ãå«ããè«æ±é 1ã7ã®ããããäžé ã«èšèŒã®å»è¬ã
- åèšæäœããããããSEQ ID No: 46ãSEQ ID No: 47ããã³SEQ ID No: 48ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 49ãAASããã³SEQ ID No: 50ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [148]ãå«ããè«æ±é 1ã6ã®ããããäžé ã«èšèŒã®å»è¬ã
- åèšæäœããSEQ ID No: 5ãå«ãVHé åããã³SEQ ID No: 6ãå«ãVLé å [148]ãå«ããè«æ±é 9ã«èšèŒã®å»è¬ã
- åèšæäœããããããSEQ ID No: 114ãSEQ ID No: 115ããã³SEQ ID No: 116ã®CDR1ãCDR2ããã³CDR3é åãå«ãVHé åïŒãªãã³ã«ããããSEQ ID No: 117ãDASããã³SEQ ID No: 118ã®CDR1ãCDR2ããã³CDR3é åãå«ãVLé å [733]ãå«ããè«æ±é 1ã6ã®ããããäžé ã«èšèŒã®å»è¬ã
- åèšæäœããSEQ ID No: 34ãå«ãVHé åããã³SEQ ID No: 35ãå«ãVLé å [733]ãå«ããè«æ±é 11ã«èšèŒã®å»è¬ã
- åèšãªã³ã«ãŒããåèšæäœã®(éšå)éå ã«ãã£ãŠåŸããã該æäœã®ã¹ã«ããããªã«æ®åºã«çµåãããŠãããè«æ±é 1ã12ã®ããããäžé ã«èšèŒã®å»è¬ã
- å¹³åçãªpã®æ°ã4ã§ãããè«æ±é 1ã13ã®ããããäžé ã«èšèŒã®å»è¬ã
- åèšADCãã28æ¥éã®ãµã€ã¯ã«ã®1æ¥ç®ã8æ¥ç®ãããã³15æ¥ç®ã«æäžãããããã«çšããããããšãç¹åŸŽãšãããè«æ±é 1ã14ã®ããããäžé ã«èšèŒã®å»è¬ã
- åèšADCã®çšéããåèšå¯Ÿè±¡è ã®äœé1kgããã0.45mgã2.0mgã§ãããäŸãã°ã0.45mg/kgã®çšéã0.5mg/kgã®çšéã0.6mg/kgã®çšéã0.7mg/kgã®çšéã0.8mg/kgã®çšéã0.9mg/kgã®çšéã1.0mg/kgã®çšéã1.1mg/kgã®çšéã1.2mg/kgã®çšéã1.3mg/kgã®çšéã1.4mg/kgã®çšéã1.5mg/kgã®çšéã1.6mg/kgã®çšéã1.7mg/kgã®çšéã1.8mg/kgã®çšéã1.9mg/kgã®çšéããŸãã¯2.0mg/kgã®çšéã§ãããè«æ±é 1ã15ã®ããããäžé ã«èšèŒã®å»è¬ã
- åèš28æ¥éã®ãµã€ã¯ã«ã®æ°ãã2ã48ãäŸãã°2ã36ãäŸãã°2ã24ãäŸãã°2ã15ãäŸãã°2ã12ãäŸãã°ã2ãµã€ã¯ã«ã3ãµã€ã¯ã«ã4ãµã€ã¯ã«ã5ãµã€ã¯ã«ã6ãµã€ã¯ã«ã7ãµã€ã¯ã«ã8ãµã€ã¯ã«ã9ãµã€ã¯ã«ã10ãµã€ã¯ã«ã11ãµã€ã¯ã«ããŸãã¯12ãµã€ã¯ã«ã§ãããè«æ±é 1ã16ã®ããããäžé ã«èšèŒã®å»è¬ã
- åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã0.45mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ãããã«çšããããããšãç¹åŸŽãšãããè«æ±é 1ã17ã®ããããäžé ã«èšèŒã®å»è¬ã
- åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã0.6mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ãããã«çšããããããšãç¹åŸŽãšãããè«æ±é 1ã17ã®ããããäžé ã«èšèŒã®å»è¬ã
- åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã0.8mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ãããã«çšããããããšãç¹åŸŽãšãããè«æ±é 1ã17ã®ããããäžé ã«èšèŒã®å»è¬ã
- åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã1.0mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ãããã«çšããããããšãç¹åŸŽãšãããè«æ±é 1ã17ã®ããããäžé ã«èšèŒã®å»è¬ã
- åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã1.2mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ãããã«çšããããããšãç¹åŸŽãšãããè«æ±é 1ã17ã®ããããäžé ã«èšèŒã®å»è¬ã
- åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã1.4mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ãããã«çšããããããšãç¹åŸŽãšãããè«æ±é 1ã17ã®ããããäžé ã«èšèŒã®å»è¬ã
- åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã1.6mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ãããã«çšããããããšãç¹åŸŽãšãããè«æ±é 1ã17ã®ããããäžé ã«èšèŒã®å»è¬ã
- åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã1.8mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ãããã«çšããããããšãç¹åŸŽãšãããè«æ±é 1ã17ã®ããããäžé ã«èšèŒã®å»è¬ã
- åèšADCã28æ¥éæ²»çãµã€ã¯ã«ã§å°ãªããšã4ãµã€ã¯ã«ã«ããã£ãŠæäžããããã®éãåæ²»çãµã€ã¯ã«ã«ãããŠè©²ADCã2.0mg/kgäœéã®çšéã§é±1åãé£ç¶ããŠ3é±éæäžããããã®åŸã«åèšæäœè¬ç©ã³ã³ãžã¥ã²ãŒããæäžãããªãäŒè¬é±ãç¶ãããã«çšããããããšãç¹åŸŽãšãããè«æ±é 1ã17ã®ããããäžé ã«èšèŒã®å»è¬ã
- åèšæ²»çãµã€ã¯ã«ã®åŸã«ç¶æçæ³ãå®æœãããããã«çšããããããšãç¹åŸŽãšãããè«æ±é 1ã26ã®ããããäžé ã«èšèŒã®å»è¬ã
- åèšç¶æçæ³ããåèšADCã3é±éã«1åãäŸãã°21æ¥éãµã€ã¯ã«ã®1æ¥ç®ã«ãæäžããããšãå«ããè«æ±é 27ã«èšèŒã®å»è¬ã
- åèšç¶æçæ³ã®ããã®ADCã®çšéããåèšå¯Ÿè±¡è ã®äœé1kgããã0.6mgã3.2mgã§ãããäŸãã°ãçŽ0.6mg/kgã®çšéãçŽ0.8mg/kgã®çšéãçŽ1.0mg/kgã®çšéãçŽ1.2mg/kgã®çšéãçŽ1.4mg/kgã®çšéãçŽ1.6mg/kgã®çšéãçŽ1.8mg/kgã®çšéãçŽ2.0mg/kgã®çšéãçŽ2.2mg/kgã®çšéãçŽ2.4mg/kgã®çšéãçŽ2.6mg/kgã®çšéãçŽ2.8mg/kgã®çšéãçŽ3.0mg/kgã®çšéããŸãã¯çŽ3.2mg/kgã®çšéã§ãããè«æ±é 27ãŸãã¯28ã«èšèŒã®å»è¬ã
- åèšç¶æçæ³ã21æ¥éã®ãµã€ã¯ã«ã§å®æœããã該ãµã€ã¯ã«ã®æ°ãã2ã48ãäŸãã°2ã36ãäŸãã°2ã24ãäŸãã°2ã15ãäŸãã°2ã12ãäŸãã°ã2ãµã€ã¯ã«ã3ãµã€ã¯ã«ã4ãµã€ã¯ã«ã5ãµã€ã¯ã«ã6ãµã€ã¯ã«ã7ãµã€ã¯ã«ã8ãµã€ã¯ã«ã9ãµã€ã¯ã«ã10ãµã€ã¯ã«ã11ãµã€ã¯ã«ããŸãã¯12ãµã€ã¯ã«ã§ãããè«æ±é 27ã29ã®ããããäžé ã«èšèŒã®å»è¬ã
- åèšããããAXLãçºçŸããåºåœ¢è «çãå«ããããŸãã¯AXLãçºçŸããè¡æ¶²ããã§ãããè«æ±é 1ã30ã®ããããäžé ã«èšèŒã®å»è¬ã
- åèšAXLãçºçŸããè¡æ¶²ããããçœè¡ç ãäŸãã°ãæ ¢æ§ãªã³ãæ§çœè¡ç ã骚é«æ§çœè¡ç ãæ¥æ§éªšé«æ§çœè¡ç (AML)ãããã³æ ¢æ§éªšé«æ§çœè¡ç ïŒãªã³ãè «ãäŸãã°éããžãã³ãªã³ãè «ããã³å€çºæ§éªšé«è «ãããªã矀ããéžæããããè«æ±é 31ã«èšèŒã®å»è¬ã
- åèšããããAXLãçºçŸããåºåœ¢è «çãå«ã¿ããã€èºçãäŸãã°ãéå°çŽ°èèºç(NSCLC)ããã³èºæå¹³äžç®çïŒå©Šäººç§çãäŸãã°ãåµå·£çãåå®®å èçãŸãã¯åå®®é žçïŒç²ç¶è ºçïŒç®èçãäŸãã°ãé»è²è «ïŒå€§è žçãäŸãã°ãå€§è žçè «ããã³å€§è žè ºçïŒèè±çïŒéªšãããäŸãã°è»éªšèè «ïŒä¹³çãäŸãã°ããªãã«ãã¬ãã£ãä¹³çïŒäžæ¢ç¥çµç³»ã®çãäŸãã°ãè èœè «ãæç¶çŽ°èè «ããã³ç¥çµèœçŽ°èè «ïŒçµåçµç¹çïŒç·ç¶èœçŽ°èçïŒèçãäŸãã°èçè «ïŒé é žéšçïŒè èçïŒèèçãäŸãã°è现èçïŒçèçïŒç¥çµçµç¹çïŒèµèçãäŸãã°ãèµç®¡çããã³èµè ºçïŒãªãã³ã«è»éšçµç¹èè «ãããªã矀ããéžæããããè«æ±é 31ã«èšèŒã®å»è¬ã
- åèšããããéå°çŽ°èèºç(NSCLC)ãåµå·£çãåå®®å èçãåå®®é žçãç²ç¶è ºçãããªã矀ããéžæããããè«æ±é 33ã«èšèŒã®å»è¬ã
- åèšããããããã·ã³ãããŒãŒé»å®³å€ãã»ãªã³/ãã¬ãªãã³ãããŒãŒé»å®³å€ããã³ååŠçæ³å€ãããªã矀ããéžæãããå°ãªããšã1ã€ã®æ²»çå€ã«å¯ŸããŠèæ§ã§ãããè«æ±é 31ã«èšèŒã®å»è¬ã
- åèšããã·ã³ãããŒãŒé»å®³å€ãEGFRé»å®³å€ã§ãããåèšã»ãªã³/ãã¬ãªãã³ãããŒãŒé»å®³å€ãBRAFé»å®³å€ããã³MEKé»å®³å€ãããªã矀ããéžæããããè«æ±é 35ã«èšèŒã®å»è¬ã
- åèšããããNSCLCãåµå·£çãåå®®é žçãé»è²è «ãé é žéšæå¹³äžç®ç(SCCHN)ãä¹³çãæ¶å管éè³ªè «ç(GIST)ãè èçãåç«è ºçãç¥çµèœçŽ°èè «ãèµèçãé£éçã暪çŽçèè «ãæ¥æ§éªšé«æ§çœè¡ç (AML)ããŸãã¯æ ¢æ§éªšé«æ§çœè¡ç (CML)ããéžæããããè«æ±é 35ãŸãã¯36ã«èšèŒã®å»è¬ã
- åèšããããEGFRé»å®³å€ã«èæ§ã®ããNSCLCã§ãããè«æ±é 37ã«èšèŒã®å»è¬ã
- åèšEGFRé»å®³å€ãããšã«ãããããã²ãã£ãããããã³ã¢ãã¡ãããã®ãã¡ã®å°ãªããšã1ã€ã§ãããè«æ±é 38ã«èšèŒã®å»è¬ã
- åèšããããã¿ããµã³ãŸãã¯çœéèªå°äœã«èæ§ã®ããåµå·£çã§ãããè«æ±é 37ã«èšèŒã®å»è¬ã
- åèšã¿ããµã³ããã¯ãªã¿ãã»ã«ã§ãããåèšçœéèªå°äœãã·ã¹ãã©ãã³ã§ãããè«æ±é 40ã«èšèŒã®å»è¬ã
- åèšããããã¿ããµã³ã«èæ§ã®ããåå®®é žçã§ãããè«æ±é 37ã«èšèŒã®å»è¬ã
- åèšã¿ããµã³ãããã¯ãªã¿ãã»ã«ããã³ãã»ã¿ãã»ã«ã®ãã¡ã®å°ãªããšãäžæ¹ã§ãããè«æ±é 42ã«èšèŒã®å»è¬ã
- åèšããããBRAFé»å®³å€ããã³/ãŸãã¯MEKé»å®³å€ã«èæ§ã®ããé»è²è «ã§ãããè«æ±é 37ã«èšèŒã®å»è¬ã
- åèšBRAFé»å®³å€ããã ã©ãã§ããããã³ããã©ãã§ããã®ãã¡ã®å°ãªããšãäžæ¹ã§ãããåèšMEKé»å®³å€ããã©ã¡ãããã§ãããè«æ±é 44ã«èšèŒã®å»è¬ã
- å°ãªããšã1ã€ã®ä»ã®æããå€ãšã®çµã¿åããã§äœ¿çšããããã®ãã®ã§ãããè«æ±é 35ã45ã®ããããäžé ã«èšèŒã®å»è¬ã
- åèšå°ãªããšã1ã€ã®ä»ã®æããå€ããè«æ±é 35ã45ã®ããããäžé ã«èšèŒã®å°ãªããšã1ã€ã®æ²»çå€ãå«ã¿ãåèšããããåèšçµã¿åããã«ãããå°ãªããšã1ã€ã®æ²»çå€ã«å¯ŸããŠèæ§ã§ãããè«æ±é 46ã«èšèŒã®å»è¬ã
- åèšADCãè¬åŠççµæç©äžã«å«ãŸãããè«æ±é 1ã47ã®ããããäžé ã«èšèŒã®å»è¬ã
- åèšè¬åŠççµæç©ãè¬åŠçã«èš±å®¹ãããæ äœãããã«å«ããè«æ±é 48ã«èšèŒã®å»è¬ã
- åèšè¬åŠççµæç©ãã泚å°ãŸãã¯æ³šå ¥ã«ããã奜ãŸããã¯éèå æ³šå ¥ã«ããæäžçšã«è£œå€åãããŠãããè«æ±é 48ãŸãã¯49ã«èšèŒã®å»è¬ã
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2016/066353 WO2017009258A1 (en) | 2015-07-10 | 2016-07-08 | Axl-specific antibody-drug conjugates for cancer treatment |
EPPCT/EP2016/066353 | 2016-07-08 | ||
US201662410984P | 2016-10-21 | 2016-10-21 | |
US62/410,984 | 2016-10-21 | ||
PCT/EP2017/067101 WO2018007592A1 (en) | 2016-07-08 | 2017-07-07 | New dosage regimens for antibody drug conjugates based on anti-axl antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019524713A JP2019524713A (ja) | 2019-09-05 |
JP2019524713A5 true JP2019524713A5 (ja) | 2020-08-13 |
Family
ID=60921579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019500471A Pending JP2019524713A (ja) | 2016-07-08 | 2017-07-07 | æïœïœïœæäœã«åºã¥ãæäœè¬ç©ã³ã³ãžã¥ã²ãŒãã®ããã®æ°ããæè¬ã¬ãžã¡ã³ |
Country Status (5)
Country | Link |
---|---|
US (1) | US20190233522A1 (ja) |
EP (1) | EP3481868A1 (ja) |
JP (1) | JP2019524713A (ja) |
MA (1) | MA45625A (ja) |
WO (1) | WO2018007592A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110291089B (zh) | 2017-01-17 | 2022-05-27 | æµ·åžçåå°Œå æ¯è¡ä»œæéå ¬åž | çšäºä¿è¿èåçæè åå°æé¢é²èç»èæ»äº¡çèçœæ¿é ¶æå¶å |
US20210070869A1 (en) * | 2018-04-10 | 2021-03-11 | Genmab A/S | Axl-specific antibodies for cancer treatment |
WO2020065396A1 (en) * | 2018-09-26 | 2020-04-02 | Genmab A/S | Axl-specific antibodies for treatment of non-small cell lung cancer |
WO2021158962A2 (en) | 2020-02-06 | 2021-08-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | T cell receptors targeting defective dna repair proteins |
US10822379B1 (en) | 2020-03-12 | 2020-11-03 | University of Pittsburghâof the Commonwealth System of Higher Education | Molecules that bind to SARS-CoV-2 |
EP4230222A1 (en) | 2022-02-17 | 2023-08-23 | Oxsonics Limited | Combination therapy with an anti-axl antibody-pbd conjugate and nanocups |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
BRPI0619056A2 (pt) | 2005-11-28 | 2011-09-20 | Genmab As | anticorpo monovalente, método para preparar e produzir um antcorpo monovalente, construção de ácido nucleico, célula hospedeira, imunoconjugado, uso de um anticorpo monovalente, e, composição farmacêutica |
US20100048503A1 (en) * | 2007-01-19 | 2010-02-25 | Eisai R & D Management Co., Ltd. | Composition for treatment of pancreatic cancer |
US9211319B2 (en) | 2009-01-09 | 2015-12-15 | Seattle Genetics, Inc. | Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates |
US20160106861A1 (en) | 2013-04-26 | 2016-04-21 | Spirogen Sarl | Axl antibody-drug conjugate and its use for the treatment of cancer |
EP3013320A4 (en) * | 2013-06-28 | 2017-02-08 | Pfizer Inc. | Docetaxel polymeric nanoparticles for cancer treatment |
SG11201607133QA (en) * | 2014-04-08 | 2016-09-29 | Seattle Genetics Inc | Optimal dosing of a cd19-antibody drug conjugate |
SI3169706T1 (sl) * | 2014-07-11 | 2020-04-30 | Genmab A/S | Protitelesa, ki veÅŸejo AXL |
US10398774B2 (en) * | 2014-12-09 | 2019-09-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies against AXL |
LT3319993T (lt) | 2015-07-10 | 2020-05-11 | Genmab A/S | Axl specifiniai antikÅ«no-vaistokonjugatai, skirti vÄÅŸiui gydyti |
-
2017
- 2017-07-07 JP JP2019500471A patent/JP2019524713A/ja active Pending
- 2017-07-07 MA MA045625A patent/MA45625A/fr unknown
- 2017-07-07 WO PCT/EP2017/067101 patent/WO2018007592A1/en unknown
- 2017-07-07 US US16/316,000 patent/US20190233522A1/en not_active Abandoned
- 2017-07-07 EP EP17742194.8A patent/EP3481868A1/en not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019524713A5 (ja) | ||
JP6215429B2 (ja) | ïœïŒïŒãç¹ç°çã«èªèããæäœãšã·ã¯ããã¹ãã¡ãããšãå«æããæè «ççµåã | |
JP7092775B2 (ja) | ãããæ²»çããããã®è¬ç©ã®èª¿è£œã«ããããæïœïœâïŒæäœãšïœïœ ïœïœïœé»å®³å€ãšãçµã¿åãããäœ¿çš | |
TWI596116B (zh) | å å«å°äžæ§èŸšèïœïœïŒïŒä¹æé«åç¡Œæ¿äœç±³ïŒïœïœïœïœïœ ïœïœïœïœïœïŒä¹æè «ç€çµå | |
US20180036395A1 (en) | Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies | |
JP7458981B2 (ja) | æäœïŒè¬ç©ã³ã³ãžã¥ã²ãŒããšãã¥ãŒããªã³é»å®³å€ã®çµã¿åãã | |
JP2020525542A5 (ja) | ||
JP2018525354A5 (ja) | ||
JP2015527318A5 (ja) | ||
TW200533339A (en) | Therapeutic synergy of anti-cancer compounds | |
JP2021059564A (ja) | çæ²»çã®ããã®äœµçšçæ³ | |
JP2015534579A5 (ja) | ||
JP2015534577A5 (ja) | ||
JP2014512356A5 (ja) | ||
HRP20160045T1 (hr) | Metoda lijeÀÅenja raka pomoÀâ u antagonista dll4 i kemoterapijskog sredstva | |
CN111132696B (zh) | Pd-1æäœåè¡šè§éäŒ è°èåèååšå¶å€æ²»çè¿ç€çè¯ç©äžççšé | |
EP3347054A1 (en) | Dosing regimens for anti-tf-antibody drug-conjugates | |
JP2018512402A5 (ja) | ||
JP6425653B2 (ja) | æè «çå€åã³æè «çå¹æå¢åŒ·å€ | |
CN112043831A (zh) | çšäºèåæ²»çä¹³è ºççå¹åç±»ååç© | |
JP2020510039A5 (ja) | ||
JP2019508433A5 (ja) | ||
JP2007511509A (ja) | ïœâïŒïŒïŒããã³ãã¯ãªã¿ãã»ã«ã®äœ¿çšãå«ãã¬ã³ã®äœµçšçæ³ | |
WO2017176565A1 (en) | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor | |
Lam et al. | Recent advances in drug-antibody immunoconjugates for the treatment of cancer |